Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LT-002-158 in adults with moderate-to-severe atopic dermatitis
CTR20263536Phase 2Active
- Sponsor
- LinkPlus Bio-Tech
- Start
- Sep 2026
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LT-002 in atopic dermatitis (AD), sponsored by LinkPlus Bio-Tech. Started Sep 2026; status: active.
02
Drugs
LT-002
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20263536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263536.